Submitted by webmaster on January 21, 2016
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in papillary renal cell carcinoma. Papillary renal cell carcinoma may be classified into hereditary and sporadic forms; subjects with either classification will be accepted into this study.
June 1, 2006 to August 1, 2010
INC280 (aka Foretinib)
POINT (-77.1274 39.0482)
recommended Papillary SOC is XXX
Add new comment